Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1995 May;95(5):2205–2214. doi: 10.1172/JCI117910

Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen.

M Alvarez 1, K Paull 1, A Monks 1, C Hose 1, J S Lee 1, J Weinstein 1, M Grever 1, S Bates 1, T Fojo 1
PMCID: PMC295832  PMID: 7738186

Abstract

Identifying new chemotherapeutic agents and characterizing mechanisms of resistance may improve cancer treatment. The Anticancer Drug Screen of the National Cancer Institute uses 60 cell lines to identify new agents. Expression of mdr-1/P-glycoprotein was measured by quantitative PCR. Expression was detected in 39 cell lines; the highest levels were in renal and colon carcinomas. Expression was also detected in all melanomas and central nervous system tumors, but in only one ovarian carcinoma and one leukemia cell line. Using a modified version of the COMPARE program, a high correlation was found between expression of mdr-1 and cellular resistance to a large number of compounds. Evidence that these compounds are P-glycoprotein substrates includes: (a) enhancement of cytotoxicity by verapamil; (b) demonstration of cross-resistance in a multidrug-resistant cell line, (c) ability to antagonize P-glycoprotein, increasing vinblastine accumulation by decreasing efflux; and (d) inhibition of photoaffinity labeling by azidopine. Identification of many heretofore unrecognized compounds as substrates indicates that P-glycoprotein has a broader substrate specificity than previously recognized. This study confirms the validity of this novel approach and provides the basis for similar studies examining a diverse group of gene products, including other resistance mechanisms, putative drug targets, and genes involved in the cell cycle and apoptosis.

Full text

PDF
2205

Images in this article

2206Image
on p.2206
2206Image
on p.2206
2212Image
on p.2212

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bech-Hansen N. T., Till J. E., Ling V. Pleiotropic phenotype of colchicine-resistant CHO cells: cross-resistance and collateral sensitivity. J Cell Physiol. 1976 May;88(1):23–31. doi: 10.1002/jcp.1040880104. [DOI] [PubMed] [Google Scholar]
  2. Bourhis J., Goldstein L. J., Riou G., Pastan I., Gottesman M. M., Bénard J. Expression of a human multidrug resistance gene in ovarian carcinomas. Cancer Res. 1989 Sep 15;49(18):5062–5065. [PubMed] [Google Scholar]
  3. Campos L., Guyotat D., Archimbaud E., Calmard-Oriol P., Tsuruo T., Troncy J., Treille D., Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood. 1992 Jan 15;79(2):473–476. [PubMed] [Google Scholar]
  4. Chan H. S., Haddad G., Thorner P. S., DeBoer G., Lin Y. P., Ondrusek N., Yeger H., Ling V. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med. 1991 Dec 5;325(23):1608–1614. doi: 10.1056/NEJM199112053252304. [DOI] [PubMed] [Google Scholar]
  5. Currier S. J., Ueda K., Willingham M. C., Pastan I., Gottesman M. M. Deletion and insertion mutants of the multidrug transporter. J Biol Chem. 1989 Aug 25;264(24):14376–14381. [PubMed] [Google Scholar]
  6. Fojo A. T., Shen D. W., Mickley L. A., Pastan I., Gottesman M. M. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol. 1987 Dec;5(12):1922–1927. doi: 10.1200/JCO.1987.5.12.1922. [DOI] [PubMed] [Google Scholar]
  7. Fojo A. T., Ueda K., Slamon D. J., Poplack D. G., Gottesman M. M., Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A. 1987 Jan;84(1):265–269. doi: 10.1073/pnas.84.1.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fojo A., Akiyama S., Gottesman M. M., Pastan I. Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res. 1985 Jul;45(7):3002–3007. [PubMed] [Google Scholar]
  9. Ford J. M., Prozialeck W. C., Hait W. N. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol. 1989 Jan;35(1):105–115. [PubMed] [Google Scholar]
  10. Goldstein L. J., Galski H., Fojo A., Willingham M., Lai S. L., Gazdar A., Pirker R., Green A., Crist W., Brodeur G. M. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst. 1989 Jan 18;81(2):116–124. doi: 10.1093/jnci/81.2.116. [DOI] [PubMed] [Google Scholar]
  11. Holmes J., Jacobs A., Carter G., Janowska-Wieczorek A., Padua R. A. Multidrug resistance in haemopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukaemia. Br J Haematol. 1989 May;72(1):40–44. doi: 10.1111/j.1365-2141.1989.tb07649.x. [DOI] [PubMed] [Google Scholar]
  12. Juliano R. L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976 Nov 11;455(1):152–162. doi: 10.1016/0005-2736(76)90160-7. [DOI] [PubMed] [Google Scholar]
  13. Kanamaru H., Kakehi Y., Yoshida O., Nakanishi S., Pastan I., Gottesman M. M. MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants. J Natl Cancer Inst. 1989 Jun 7;81(11):844–849. doi: 10.1093/jnci/81.11.844. [DOI] [PubMed] [Google Scholar]
  14. Kuwazuru Y., Yoshimura A., Hanada S., Utsunomiya A., Makino T., Ishibashi K., Kodama M., Iwahashi M., Arima T., Akiyama S. Expression of the multidrug transporter, P-glycoprotein, in acute leukemia cells and correlation to clinical drug resistance. Cancer. 1990 Sep 1;66(5):868–873. doi: 10.1002/1097-0142(19900901)66:5<868::aid-cncr2820660510>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  15. Lai G. M., Chen Y. N., Mickley L. A., Fojo A. T., Bates S. E. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer. 1991 Nov 11;49(5):696–703. doi: 10.1002/ijc.2910490512. [DOI] [PubMed] [Google Scholar]
  16. Marie J. P., Zittoun R., Sikic B. I. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood. 1991 Aug 1;78(3):586–592. [PubMed] [Google Scholar]
  17. Miller T. P., Grogan T. M., Dalton W. S., Spier C. M., Scheper R. J., Salmon S. E. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol. 1991 Jan;9(1):17–24. doi: 10.1200/JCO.1991.9.1.17. [DOI] [PubMed] [Google Scholar]
  18. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst. 1991 Jun 5;83(11):757–766. doi: 10.1093/jnci/83.11.757. [DOI] [PubMed] [Google Scholar]
  19. Murphy L. D., Herzog C. E., Rudick J. B., Fojo A. T., Bates S. E. Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochemistry. 1990 Nov 13;29(45):10351–10356. doi: 10.1021/bi00497a009. [DOI] [PubMed] [Google Scholar]
  20. Nooter K., Sonneveld P., Oostrum R., Herweijer H., Hagenbeek T., Valerio D. Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A. Int J Cancer. 1990 Feb 15;45(2):263–268. doi: 10.1002/ijc.2910450210. [DOI] [PubMed] [Google Scholar]
  21. Paull K. D., Lin C. M., Malspeis L., Hamel E. Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Res. 1992 Jul 15;52(14):3892–3900. [PubMed] [Google Scholar]
  22. Paull K. D., Shoemaker R. H., Hodes L., Monks A., Scudiero D. A., Rubinstein L., Plowman J., Boyd M. R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst. 1989 Jul 19;81(14):1088–1092. doi: 10.1093/jnci/81.14.1088. [DOI] [PubMed] [Google Scholar]
  23. Schneider J., Bak M., Efferth T., Kaufmann M., Mattern J., Volm M. P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer. 1989 Dec;60(6):815–818. doi: 10.1038/bjc.1989.372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J. T., Bokesch H., Kenney S., Boyd M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990 Jul 4;82(13):1107–1112. doi: 10.1093/jnci/82.13.1107. [DOI] [PubMed] [Google Scholar]
  25. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981 May;41(5):1967–1972. [PubMed] [Google Scholar]
  26. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Potentiation of vincristine and Adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res. 1983 May;43(5):2267–2272. [PubMed] [Google Scholar]
  27. Wu L., Smythe A. M., Stinson S. F., Mullendore L. A., Monks A., Scudiero D. A., Paull K. D., Koutsoukos A. D., Rubinstein L. V., Boyd M. R. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res. 1992 Jun 1;52(11):3029–3034. [PubMed] [Google Scholar]
  28. Zamora J. M., Pearce H. L., Beck W. T. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol. 1988 Apr;33(4):454–462. [PubMed] [Google Scholar]
  29. Zhou D. C., Marie J. P., Suberville A. M., Zittoun R. Relevance of mdr1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia. 1992 Sep;6(9):879–885. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES